Literature DB >> 11234746

Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats.

S Taheri1, J Gardiner, S Hafizi, K Murphy, C Dakin, L Seal, C Small, M Ghatei, S Bloom.   

Abstract

The primary role of the orexins was originally believed to be appetite regulation, but is now believed to be the regulation of sleep, arousal and locomotor activity. Orexin A immunoreactivity (orexin A-IR) and prepro-orexin mRNA were measured in the CNS of obese and lean Zucker rats. There were no differences in orexin A-IR or prepro-orexin mRNA levels between obese and lean Zucker rats. The orexins are therefore unlikely to be important in this model of obesity. Levels of orexin A-IR and prepro-orexin mRNA were measured in the CNS of Wistar-Kyoto (WKY) rats, which are hypoactive and have abnormal sleep architecture. Compared to Wistar rats, WKY rats had significantly lower orexin A-IR (with differences of up to 100% in some brain regions) and prepro-orexin mRNA levels. These observations suggest that the sleep and activity phenotype of the WKY strain may be related to orexin deficiency and that this strain may be a useful model of partial orexin deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11234746     DOI: 10.1097/00001756-200103050-00008

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

Review 1.  Sleep and obesity: a focus on animal models.

Authors:  Vijayakumar Mavanji; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Neurosci Biobehav Rev       Date:  2012-01-16       Impact factor: 8.989

2.  Upregulation of orexin receptor in paraventricular nucleus promotes sympathetic outflow in obese Zucker rats.

Authors:  Jing-Jing Zhou; Fang Yuan; Yi Zhang; De-Pei Li
Journal:  Neuropharmacology       Date:  2015-08-12       Impact factor: 5.250

Review 3.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

4.  Behavioral responses to orexin, orexin receptor gene expression, and spontaneous physical activity contribute to individual sensitivity to obesity.

Authors:  Claudio E Perez-Leighton; Kelsey Boland; Jennifer A Teske; Charles Billington; Catherine M Kotz
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-24       Impact factor: 4.310

Review 5.  New directions for the treatment of depression: Targeting the photic regulation of arousal and mood (PRAM) pathway.

Authors:  Hannah E Bowrey; Morgan H James; Gary Aston-Jones
Journal:  Depress Anxiety       Date:  2017-05-10       Impact factor: 6.505

6.  Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression.

Authors:  Mathieu Nollet; Philippe Gaillard; Arnaud Tanti; Virginie Girault; Catherine Belzung; Samuel Leman
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

7.  Identifying genes in monoamine nuclei that may determine stress vulnerability and depressive behavior in Wistar-Kyoto rats.

Authors:  Kimberly A Pearson; Alisson Stephen; Sheryl G Beck; Rita J Valentino
Journal:  Neuropsychopharmacology       Date:  2006-05-17       Impact factor: 7.853

8.  Elevated sleep quality and orexin receptor mRNA in obesity-resistant rats.

Authors:  V Mavanji; J A Teske; C J Billington; C M Kotz
Journal:  Int J Obes (Lond)       Date:  2010-05-25       Impact factor: 5.095

Review 9.  Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.

Authors:  Cliff H Summers; Jazmine D W Yaeger; Clarissa D Staton; David H Arendt; Tangi R Summers
Journal:  Brain Res       Date:  2018-12-24       Impact factor: 3.252

10.  High and low activity rats: elevated intrinsic physical activity drives resistance to diet-induced obesity in non-bred rats.

Authors:  Claudio E Perez-Leighton; Kelsey Boland; Charles J Billington; Catherine M Kotz
Journal:  Obesity (Silver Spring)       Date:  2013-02       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.